Pulmatrix Inc. (NASDAQ: PULM) announced on March 2, 2026 that it had terminated its merger agreement with Cullgen Inc. The termination was first notified by Cullgen on February 28, 2026, and Pulmatrix made the public announcement two days later.
The original merger agreement was signed on November 13, 2024, amended on April 7, 2025, and received Pulmatrix stockholder approval on June 16, 2025. The deal was intended to combine Pulmatrix’s inhaled therapeutic platform with Cullgen’s targeted protein‑degradation technology, but regulatory hurdles in China stalled the transaction.
Pulmatrix cited significant delays at the China Securities Regulatory Commission (CSRC) in 2025 and unmet closing conditions tied to CSRC approval as the primary reasons for the termination. The same day Pulmatrix announced the termination, Cullgen disclosed that it would be acquired by Gyre Therapeutics for approximately $300 million, suggesting that Cullgen’s strategic priorities had shifted independently of the Pulmatrix deal.
Pulmatrix’s leadership has announced that it is actively pursuing alternative merger opportunities. The company has paused its clinical programs for PUR3100 (acute migraine), PUR1800 (COPD exacerbations), and PUR1900 (fungal lung disease) in order to monetize these assets. Financially, Pulmatrix is operating with negative margins and a distressed Altman Z‑Score, and it has limited revenue growth. Management has indicated that if a new strategic transaction does not materialize, the company may consider dissolution or liquidation.
The termination marks a significant pivot for Pulmatrix, moving it from a drug‑development focus toward a transaction‑driven strategy. The company’s pipeline remains intact, with PUR3100 having received FDA acceptance for a Phase 2 study and PUR1900 having cleared a Phase 3 launch in India with partner Cipla. However, the loss of the Cullgen partnership and the ongoing regulatory delays increase the risk profile for Pulmatrix’s future growth and survival.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.